CoChat

Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).

Gaspar, Nathalie, Casanova, Michela, Sirvent, Francisco José Bautista, Venkatramani, Rajkumar, Morland, Bruce, Gambart, Marion, Thebaud, Estelle, Strauss, Sandra J, Locatelli, Franco, Gallego Melcon, Soledad, Canete, Adela, Bielack, Stefan S., Rossig, Claudia, Aerts, Isabelle, Marec-Berard, Perrine, Kraljevic, Silvija, Hayato, Seiichi, He, Cixin, Dutcus, Corina E., Campbell-Hewson, Quentin · 2018 · Journal of Clinical Oncology
Cited by 31

The DOI matches its Crossref record.

Abstract

11527 Background: LEN is a multikinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. In human pediatric OS xenograft models, LEN enhanced the antitumor activity of IFM + ETP. In a phase (Ph) 2 study of sorafenib in pts with unresectable high-grade OS, progression-free survival at 4 months (PFS-4) was 46%. We report emerging data from a Ph 2 single-agent LEN expansion cohort and Ph 1b combination dose-finding cohort of LEN + ETP + IFM in pts with relapsed/refractory OS. Methods: Pts were age 2 to ≤25 years, had relapsed OS, and had < 2 prior VEGF-targeted therapies. The recommended dose (RD; 14 mg/m2) from Ph 1 was used in Ph 2. In Ph 1b, a 20% reduction of LEN (11 mg/m2/day) was used as starting dose in combination with IFM 3000 mg/m2 + ETP 100 mg/m2 daily/3 days. Ph 2 and Ph 1b primary endpoints were PFS-4 per RECIST 1.1 and RD of the combination. Secondary objectives included best overall response (BOR), objective response rate, PFS, safety, and PK. Data cutoff was October 6, 2017. Results: In Ph 2, 16 pts received LEN 14 mg/m2. Median (min, max) number of cycles received was 3.0 (1, 9). Most common any-grade TEAEs were diarrhea, hypothyroidism, and proteinuria (43.8% each). Most common Grade (G) 3 or 4 TEAEs were back pain and dyspnea (12.5% each). One pt discontinued due to TEAEs (myelodysplastic syndrome); 5 of 15 evaluable pts achieved PFS-4 and BOR was PR (n = 1) and SD (n = 7). In Ph 1b, 7 pts received LEN 11 (LEN 11 mg/m2 + IFM + ETP) and 6 pts received LEN 14 (LEN 14 mg/m2 + IFM + ETP). 1 pt had a DLT at LEN 11 (G3 thrombocytopenia) and 2 pts had DLTs at LEN 14 (G4 thrombocytopenia with G3 bleeding in 1 pt; G2 oral dysesthesia, G2 back pain, and G1 muscle spasms in 1 pt). G ≥3 TEAEs occurred in 85.7% and 66.7% of LEN 11 and LEN 14 pts, respectively. No pts discontinued due to TEAEs. BOR was PR (n = 1) and SD (n = 5). AUC at steady state of LEN and distributions of interindividual variability of oral clearance were comparable between LEN single agent and the combination. Conclusions: In Ph 2, LEN at 14 mg/m2 achieved PFS-4 in 5 pts; BOR was PR in 1 pt and SD in 7 pts. In Ph 1b, LEN + chemotherapy had a manageable safety profile. The study is ongoing and updated data will be presented. Clinical trial information: NCT02432274.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.36.15_suppl.11527

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 31

Metadata

Authors
Gaspar, N., Casanova, M., Sirvent, F. J. B., Venkatramani, R., Morland, B., Gambart, M., Thebaud, E., Strauss, S. J., Locatelli, F., Gallego Melcon, S., Canete, A., Bielack, S. S., Rossig, C., Aerts, I., Marec-Berard, P., Kraljevic, S., Hayato, S., He, C., Dutcus, C. E., & Campbell-Hewson, Q.
Venue
Journal of Clinical Oncology
Published
2018-05-20
Volume
36
Issue
15_suppl
Pages
11527-11527
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2889673034
Cited by
31
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS). https://app.cochat.ai/papers/10.1200/jco.2018.36.15_suppl.11527
The paper
Gaspar, N., Casanova, M., Sirvent, F. J. B., Venkatramani, R., Morland, B., Gambart, M., Thebaud, E., Strauss, S. J., Locatelli, F., Gallego Melcon, S., Canete, A., Bielack, S. S., Rossig, C., Aerts, I., Marec-Berard, P., Kraljevic, S., Hayato, S., He, C., Dutcus, C. E., & Campbell-Hewson, Q. (2018). Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.36.15_suppl.11527

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.